세계의 신경피부질환 시장 보고서(2025년)

A neurocutaneous disorder is a group of genetic conditions that affect both the nervous system and the skin, often present from birth due to mutations that disrupt normal cell growth and development. These disorders typically manifest with visible skin abnormalities such as birthmarks, lesions, or tumors, along with neurological complications including seizures, developmental delays, or cognitive impairments.

The primary types of neurocutaneous disorders include neurofibromatosis, tuberous sclerosis complex, Sturge-Weber syndrome, angiomatosis, and hypomelanosis of Ito. Neurofibromatosis encompasses NF1, NF2, and schwannomatosis, genetic conditions that cause tumor growth along nerves. Treatments include pharmacological therapy, surgical intervention, laser therapy, and physical or psychosocial support. These disorders affect various age groups, including pediatric patients (0-18 years), adults (19-65 years), and geriatric patients (65 years and above), and range in severity from mild to critical cases. Key end-users include hospitals, specialist clinics, homecare settings, research organizations, and pharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The neurocutaneous disorder market research report is one of a series of new reports from The Business Research Company that provides neurocutaneous disorder market statistics, including neurocutaneous disorder industry global market size, regional shares, competitors with a neurocutaneous disorder market share, detailed neurocutaneous disorder market segments, market trends and opportunities, and any further data you may need to thrive in the neurocutaneous disorder industry. This neurocutaneous disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurocutaneous disorder market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.22 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. Growth in the historic period was driven by the rising prevalence of genetic disorders, increasing awareness of rare neurological conditions, greater adoption of diagnostic imaging, higher patient visits to specialty clinics, and growing clinical focus on pediatric neurology.

The neurocutaneous disorder market size is expected to see strong growth in the next few years. It will grow to $3.04 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. Growth in the forecast period is expected to be supported by increasing demand for targeted drug therapies, expansion of clinical trial activities for rare diseases, rising collaborations among research institutes, wider adoption of genetic testing services, and higher healthcare expenditure on neurological care. Key trends anticipated for the forecast period include advancements in genomic sequencing, innovation in gene therapy applications, increased investment in research and development for novel treatments, developments in digital health monitoring tools, and progress in biomarker-based diagnostics.

The growing prevalence of genetic disorders is anticipated to support the expansion of the neurocutaneous disorder market. Genetic disorders are medical conditions caused by changes or abnormalities in an individual's DNA, which may be inherited or occur spontaneously. Neurocutaneous disorders, including conditions such as tuberous sclerosis complex and neurofibromatosis, are caused by specific genetic mutations that affect both the nervous system and the skin, resulting in a combination of neurological symptoms and distinct dermatological signs. Advances in genetic testing and increased awareness are contributing to earlier diagnosis, which has led to a higher reported prevalence. For example, in November 2024, the Centers for Disease Control and Prevention, a government agency based in the United States, reported that approximately one in every thirty-three newborns in the country is born with a birth defect, many of which are linked to genetic causes. Therefore, the increasing incidence of genetic disorders is driving the growth of the neurocutaneous disorder market.

Leading companies within the neurocutaneous disorder market are prioritizing regulatory approvals to broaden their treatment offerings, improve patient outcomes, and meet growing demand for innovative therapies. Regulatory approvals refer to formal authorization from government authorities that permit the testing, marketing, or sale of a pharmaceutical product after confirming its safety and efficacy. For instance, in September 2025, AstraZeneca, a pharmaceutical and biotechnology company based in the United Kingdom, received approval from the Food and Drug Administration to market selumetinib, known commercially as Koselugo, for use in pediatric patients aged one year and older with neurofibromatosis type one who present with symptomatic and inoperable plexiform neurofibromas. This approval extends the previous indication, which covered children aged two years and older. Selumetinib is a MEK inhibitor that works by targeting the MAPK pathway, which plays a role in tumor development in neurofibromatosis type one. The treatment is administered orally twice daily and continued until disease progression or intolerable side effects arise. Common side effects include gastrointestinal issues, skin reactions, cardiac complications, and vision-related problems. This regulatory approval provides a vital treatment option for younger children affected by these complex and often disfiguring tumors, which are typically challenging to remove surgically.

In October 2022, Pasithea Therapeutics Corporation, a biotechnology company based in the United States, acquired AlloMek Therapeutics for an undisclosed amount. Through this acquisition, Pasithea seeks to expand its drug development pipeline focused on central nervous system disorders, with a particular emphasis on rare genetic conditions known as RASopathies. The deal is expected to support long-term growth and create potential synergies with Pasithea's ongoing research in multiple sclerosis. AlloMek Therapeutics is a pharmaceutical company based in the United States that developed CIP-137401, a macrocyclic MEK inhibitor aimed at treating neurocutaneous disorders.

Major players in the neurocutaneous disorder market are Merck KGaA, AbbVie Inc., Sanofi S.A., Novartis AG, Recursion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific SE, Fosun Pharmaceutical Group Co. Ltd., ioMarin Pharmaceutical Inc., Simcere Pharmaceutical Group, Marinus Pharmaceuticals Inc., Inhibikase Therapeutics Inc., Healx Limited, NF2 Therapeutics Inc., NFlection Therapeutics Inc., Ovid Therapeutics Inc., CureAge Therapeutics, GW Pharmaceuticals plc.

North America was the largest region in the neurocutaneous disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurocutaneous disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurocutaneous disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurocutaneous disorder market includes revenues earned by entities by providing services, such as pharmacological treatment, medical consultation and diagnosis, psychological and behavioral support, and clinical trials and research participation. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurocutaneous Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurocutaneous disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurocutaneous disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurocutaneous disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Neurocutaneous Disorder: Neurofibromatosis; Tuberous Sclerosis Complex; Sturge-Weber Syndrome; Angiomatosis; Hypomelanosis Of Ito
• 2) By Treatment Type: Pharmacological Treatment; Surgical Intervention; Laser Therapy; Physical Therapy; Psychosocial Support
• 3) By Age Group: Pediatric Patients (0-18 Years); Adult Patients (19-65 Years); Geriatric Patients (65 Years And Above)
• 4) By Severity Of Condition: Mild Cases; Moderate Cases; Severe Cases; Critical Cases
• 5) By End User: Hospitals; Specialist Clinics; Homecare Settings; Research Organizations; Pharmaceutical Companies
• Subsegments:
• 1) By Neurofibromatosis: Peripheral Neurofibromatosis; Central Neurofibromatosis; Plexiform Neurofibromatosis
• 2) By Tuberous Sclerosis Complex: Classic Tuberous Sclerosis; Infantile-Onset Tuberous Sclerosis; Adult-Onset Tuberous Sclerosis
• 3) By Sturge-Weber Syndrome: Facial Sturge-Weber Syndrome; Cerebral Sturge-Weber Syndrome; Ophthalmic Sturge-Weber Syndrome
• 4) By Angiomatosis: Generalized Angiomatosis; Localized Angiomatosis; Mixed Angiomatosis
• 5) By Hypomelanosis Of Ito: Linear Hypomelanosis; Segmental Hypomelanosis; Whorled Hypomelanosis
• Companies Mentioned: Merck KGaA; AbbVie Inc.; Sanofi S.A.; Novartis AG; Recursion Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Labcorp Holdings Inc.; Quest Diagnostics Incorporated; Eurofins Scientific SE; Fosun Pharmaceutical Group Co. Ltd.; ioMarin Pharmaceutical Inc.; Simcere Pharmaceutical Group; Marinus Pharmaceuticals Inc.; Inhibikase Therapeutics Inc.; Healx Limited; NF2 Therapeutics Inc.; NFlection Therapeutics Inc.; Ovid Therapeutics Inc.; CureAge Therapeutics; GW Pharmaceuticals plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurocutaneous Disorder Market Characteristics

3. Neurocutaneous Disorder Market Trends And Strategies

4. Neurocutaneous Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neurocutaneous Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurocutaneous Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurocutaneous Disorder Market Growth Rate Analysis
• 5.4. Global Neurocutaneous Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurocutaneous Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurocutaneous Disorder Total Addressable Market (TAM)

6. Neurocutaneous Disorder Market Segmentation

• 6.1. Global Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurofibromatosis
• Tuberous Sclerosis Complex
• Sturge-Weber Syndrome
• Angiomatosis
• Hypomelanosis Of Ito
• 6.2. Global Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacological Treatment
• Surgical Intervention
• Laser Therapy
• Physical Therapy
• Psychosocial Support
• 6.3. Global Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients (0-18 Years)
• Adult Patients (19-65 Years)
• Geriatric Patients (65 Years And Above)
• 6.4. Global Neurocutaneous Disorder Market, Segmentation By Severity Of Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Cases
• Moderate Cases
• Severe Cases
• Critical Cases
• 6.5. Global Neurocutaneous Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialist Clinics
• Homecare Settings
• Research Organizations
• Pharmaceutical Companies
• 6.6. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Neurofibromatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral Neurofibromatosis
• Central Neurofibromatosis
• Plexiform Neurofibromatosis
• 6.7. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Tuberous Sclerosis Complex, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Tuberous Sclerosis
• Infantile-Onset Tuberous Sclerosis
• Adult-Onset Tuberous Sclerosis
• 6.8. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Sturge-Weber Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Facial Sturge-Weber Syndrome
• Cerebral Sturge-Weber Syndrome
• Ophthalmic Sturge-Weber Syndrome
• 6.9. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Angiomatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generalized Angiomatosis
• Localized Angiomatosis
• Mixed Angiomatosis
• 6.10. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Hypomelanosis Of Ito, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linear Hypomelanosis
• Segmental Hypomelanosis
• Whorled Hypomelanosis

7. Neurocutaneous Disorder Market Regional And Country Analysis

• 7.1. Global Neurocutaneous Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurocutaneous Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurocutaneous Disorder Market

• 8.1. Asia-Pacific Neurocutaneous Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurocutaneous Disorder Market

• 9.1. China Neurocutaneous Disorder Market Overview
• 9.2. China Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurocutaneous Disorder Market

• 10.1. India Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurocutaneous Disorder Market

• 11.1. Japan Neurocutaneous Disorder Market Overview
• 11.2. Japan Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurocutaneous Disorder Market

• 12.1. Australia Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurocutaneous Disorder Market

• 13.1. Indonesia Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurocutaneous Disorder Market

• 14.1. South Korea Neurocutaneous Disorder Market Overview
• 14.2. South Korea Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurocutaneous Disorder Market

• 15.1. Western Europe Neurocutaneous Disorder Market Overview
• 15.2. Western Europe Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurocutaneous Disorder Market

• 16.1. UK Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurocutaneous Disorder Market

• 17.1. Germany Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurocutaneous Disorder Market

• 18.1. France Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurocutaneous Disorder Market

• 19.1. Italy Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurocutaneous Disorder Market

• 20.1. Spain Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurocutaneous Disorder Market

• 21.1. Eastern Europe Neurocutaneous Disorder Market Overview
• 21.2. Eastern Europe Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurocutaneous Disorder Market

• 22.1. Russia Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurocutaneous Disorder Market

• 23.1. North America Neurocutaneous Disorder Market Overview
• 23.2. North America Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurocutaneous Disorder Market

• 24.1. USA Neurocutaneous Disorder Market Overview
• 24.2. USA Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurocutaneous Disorder Market

• 25.1. Canada Neurocutaneous Disorder Market Overview
• 25.2. Canada Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurocutaneous Disorder Market

• 26.1. South America Neurocutaneous Disorder Market Overview
• 26.2. South America Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurocutaneous Disorder Market

• 27.1. Brazil Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurocutaneous Disorder Market

• 28.1. Middle East Neurocutaneous Disorder Market Overview
• 28.2. Middle East Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurocutaneous Disorder Market

• 29.1. Africa Neurocutaneous Disorder Market Overview
• 29.2. Africa Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurocutaneous Disorder Market Competitive Landscape And Company Profiles

• 30.1. Neurocutaneous Disorder Market Competitive Landscape
• 30.2. Neurocutaneous Disorder Market Company Profiles
  • 30.2.1. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Recursion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Neurocutaneous Disorder Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Labcorp Holdings Inc.
• 31.3. Quest Diagnostics Incorporated
• 31.4. Eurofins Scientific SE
• 31.5. Fosun Pharmaceutical Group Co. Ltd.
• 31.6. ioMarin Pharmaceutical Inc.
• 31.7. Simcere Pharmaceutical Group
• 31.8. Marinus Pharmaceuticals Inc.
• 31.9. Inhibikase Therapeutics Inc.
• 31.10. Healx Limited
• 31.11. NF2 Therapeutics Inc.
• 31.12. NFlection Therapeutics Inc.
• 31.13. Ovid Therapeutics Inc.
• 31.14. CureAge Therapeutics
• 31.15. GW Pharmaceuticals plc

32. Global Neurocutaneous Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurocutaneous Disorder Market

34. Recent Developments In The Neurocutaneous Disorder Market

35. Neurocutaneous Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Neurocutaneous Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurocutaneous Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurocutaneous Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer